On Saturday, Aug. 29, Vanderbilt-Ingram Cancer Center is convening clinicians from across the Middle Tennessee area for a day of collaboration and connection at the Stem Cell Transplant and Cellular Therapy Symposium, held at the Loews Nashville Hotel at Vanderbilt Plaza from 8 a.m. to 4 p.m.

The event theme is “Emerging Applications of Novel Therapies in Hematologic Disorders and Solid Tumors.”

Adetola Kassim, MBBS, MS, Professor of Medicine in the Division of Hematology and Oncology, is the symposium chair and moderator. 

Kassim said, “Advances in treatment for hematologic disorders and solid tumors continue to reshape what’s possible for patients. This symposium offers providers a forum to learn from experts, share perspectives, and apply the latest evidence to improve outcomes for their patients.”

Sessions will focus on current advances in stem cell transplantation and cancer cell therapy, and emerging applications of these novel therapies in hematologic disorders and solid tumors.

The event will begin with a welcome from Ben Ho Park, MD, PhD, Director of Vanderbilt-Ingram and Benjamin F. Byrd Jr. Professor of Oncology, and Karen Proctor, MSN, RN, NE-BC, Administrative Director of Nursing.

A limited number of tickets are available for Vanderbilt Health employees at a discounted rate. Use these codes at checkout:

1. Physicians: VUMCMD
2. Advanced practice providers, fellows and nurses: VUMCAPPFEL

To register and view the agenda in advance, click here. Email questions to sct_symposium@vumc.org.

The post Discover what’s next in cancer cell therapy at Aug. 29 symposium appeared first on Vanderbilt Health News.

The cellular therapy programs at Vanderbilt-Ingram Cancer Center, Monroe Carell Jr. Children’s Hospital at Vanderbilt, and the VA Tennessee Valley Healthcare System have received reaccreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).

Founded in 1995, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a nonprofit corporation co-founded by the International Society for Cell and Gene Therapy and the American Society for Transplantation and Cellular Therapy for the purposes of voluntary inspection and accreditation in the field of cellular therapy.

“FACT is an internationally recognized accrediting body for hospitals that offer stem cell transplant and cellular therapy, and recognition by FACT indicates that the accredited institution has met the most rigorous standard in every aspect of cellular therapy,” said Adetola Kassim, MD, professor of Medicine and director of the Vanderbilt Stem Cell Transplant and Cellular Therapy Program. “This covers the entire spectrum of stem cell therapy from clinical care to donor management, cell collection, processing, storage, transplant, administration and cell release.”

The Vanderbilt and VA Tennessee Valley Healthcare System programs received accreditation notification on April 14 after on-site inspections in October 2024. The accreditation is effective for three years.

“Congratulations to the entire Vanderbilt University Medical Center and VA Tennessee Valley Healthcare System team on achieving FACT accreditation and providing quality care for the people we serve,” Kassim said.

The post Three Vanderbilt-affiliated cellular therapy programs receive reaccreditation appeared first on VUMC News.